News
WestKam Gold Corp. Completes Over-Subscribed Non-Brokered Private Placement
3+ week, 5+ day ago (113+ words) February 11, 2026 07:15 ET "| Source: WestKam Gold Corp WestKam Gold Corp All securities issued under the Offering are subject to a hold period expiring June 11, 2026, in accordance with applicable securities laws and the policies of the TSX Venture Exchange. WestKam Gold Corp....
Smarkets, Backed by Trading Giant Susquehanna, Files for CFTC License to Enter U.S. Prediction Markets
13+ hour, 32+ min ago (593+ words) Smarkets files for CFTC license to enter U.S. prediction markets, bringing exchange-style trading and transparent pricing backed by Susquehanna.......
Kelli Christina Announces Pre-Order Campaign for In Good Faith: A Whistleblower’s War Against a Broken System
1+ hour, 24+ min ago (359+ words) March 10, 2026 07:00 ET "| Source: KDC-Making A Difference, LLC Follow KDC-Making A Difference, LLC DALLAS, TEXAS, March 10, 2026 (GLOBE NEWSWIRE) -- Author and entrepreneur Kelli Christina announced the launch of the pre-order campaign for her upcoming book, In Good Faith: A Whistleblower's War Against…...
Enterprise AI Automation Budgets Driving 53% Surge in use of ‘AI Workers’
2+ hour, 19+ min ago (416+ words) March 10, 2026 06:05 ET "| Source: Jitterbit Follow Jitterbit ALAMEDA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Jitterbit, a global leader in accelerating business transformation for enterprise systems, announced telling new data via its 2026 AI Automation Benchmark Report. Surveying 1,500 IT decision-makers, Jitterbit's research shows that financial…...
Kasinoilmankierratysta.fi: Finland’s Uniform Bonus Rules Risk Driving Players to the Black Market
16+ hour, 40+ min ago (421+ words) While the proposed maximum 5x wagering requirement has received public attention, the platform emphasises that this is not the core issue. The more problematic element, according to Kasinoilmankierratysta.fi, is the prohibition on activity-based or personalised bonuses, effectively requiring that all…...
Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets
4+ mon, 2+ week ago (205+ words) October 22, 2025 12:05 ET "| Source: Frontier Medicines Frontier Medicines " FMC-376 demonstrated robust anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream pathways compared to sotorasib " " FMC-220 potently and selectively restored p53 tumor suppressor function and delivered tumor regressions, including…...
Samuel Adams Unveils “Our City. Our Beer.” Variety Pack Crafted Alongside Derrick White, Garrett Crochet, Julian Edelman and Zdeno Chara
17+ hour, 21+ min ago (279+ words) 09 mars 2026 11h03 HE "| Source: Samuel Adams Samuel Adams All-Star LineupThe "Our City. Our Beer." Variety Pack features a wheat ale, an American pale ale, a lager, and a pilsner - four of the five top favorite styles for New England craft drinkers,…...
Xenon Pharmaceuticals Announces Proposed Public Offering
12+ hour, 23+ min ago (159+ words) 09 mars 2026 16h01 HE "| Source: Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals Inc. J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair are acting as joint book-running managers for the proposed offering. Baird is acting as lead manager for the proposed offering....
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
14+ hour, 46+ min ago (136+ words) 09 mars 2026 13h37 HE "| Source: Ipsen Pharma Ipsen Pharma The withdrawal is not expected to impact the Company's financial guidance. About SYMPHONY-1SYMPHONY1 (EZH302; NCT04224493) is an Ipsenled global Phase Ib/III study evaluating Tazverik" in combination with lenalidomide and rituximab (R) as a secondline therapy…...
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
1+ week, 3+ day ago (306+ words) February 27, 2026 06:20 ET "| Source: Ipsen Pharma Ipsen Pharma Today, there is no global uniform consensus on standard of care for most children as they progress with this rare brain tumor,vi and there is a considerable need for approved therapies that…...